에 대한 최신 뉴스 Fortrea Holdings (NASDAQ:FTRE) 주식

FORTREA HOLDINGS INC

Fortrea Holdings

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

WallStreet.NYSE

News

Pre-Market Outlook

Markets

Trading Ideas

BEKE

FTRE

MNDY

월요일 아침 (현지 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데, 오늘 투자자들의 관심을 끌 수 있는 일부 주식은 다음과 같다: 월스트리트는 먼데이닷컴(NASDAQ:MNDY)이 개장 전 2억 2,877만 달러의 매출과 주당 56센트의 분기 이익을 보고할 것으로 예상하고 있다. 먼데이닷컴의 주가는 시간외 거래에서 1% 상승한 228.00달러를 기록했다.

월요일 주목해야 할 주식: 먼데이닷컴, 선 라이프 파이낸셜 그리고  3종목

Fortrea Holdings Inc

Barclays analyst Ramsey El-Assal maintains Green Dot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDOT#NYSE">GDOT</a>) with a Underweight and raises the price target from $7 to $10.

Price Target

Analyst Ratings

GDOT

Barclays Maintains Underweight on Green Dot, Raises Price Target to $10

Barclays analyst Julian Mitchell maintains Gates Industrial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTES#NYSE">GTES</a>) with a Overweight and raises the price target from $22 to $23.

GTES

Barclays Maintains Overweight on Gates Industrial Corp, Raises Price Target to $23

B of A Securities analyst Derek Hewett maintains Golub Capital BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBDC#NASDAQ">GBDC</a>) with a Buy and lowers the price target from $16.5 to $15.5.

GBDC

B of A Securities Maintains Buy on Golub Capital BDC, Lowers Price Target to $15.5

Barclays analyst Adrienne Yih maintains Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) with a Overweight and lowers the price target from $24 to $14.

Barclays Maintains Overweight on Foot Locker, Lowers Price Target to $14

WIIM

PSNY

PSNY stock has given up its prior gain. Polestar Automotive Holding shares were trading higher after the company reported a year-over-year increase in Q1 retail sales results.

B of A Securities analyst Ken Hoexter maintains CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) with a Neutral and raises the price target from $30 to $31.

B of A Securities Maintains Neutral on CSX, Raises Price Target to $31

Guggenheim analyst John Heinbockel reiterates US Foods Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) with a Buy and maintains $80 price target.

Reiteration

USFD

Guggenheim Reiterates Buy on US Foods Hldg, Maintains $80 Price Target

<a href="https://www.youtube.com/watch?v=u9kS0t0jkJs" title="https://www.youtube.com/watch?v=u9kS0t0jkJs">https://www.youtube.com/watch?v=u9kS0t0jkJs</a>

Biotech

Macro Economic Events

Global

Economics

General

President Trump Signs Executive Order On Drug Prices; Says European Union Has Been Brutal On Drug Prices; Will No Longer Tolerate Profiteering From Big Pharma; EU Was Most Difficult On Drug Subsidies; Brought Up Weight Loss Drugs With Drug Companies

Barclays analyst Benjamin Theurer maintains Fomento Economico (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMX#NYSE">FMX</a>) with a Equal-Weight and raises the price target from $102 to $108.

Fomento Economico Mexicano S.A.B. De C.V.

Barclays Maintains Equal-Weight on Fomento Economico, Raises Price Target to $108

GOLD

PAAS

Shares of precious metals stocks are trading lower as gold and silver drop after the US and China agreed to a temporary reduction in most tariffs on each other's goods. This could be driving a rotation out of safe-haven assets.

FTRE stock has given up its prior gain. Fortrea Holdings shares were trading higher after the company reported better-than-expected Q1 financial results.

B of A Securities analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) with a Neutral and lowers the price target from $47 to $44.

KYMR

B of A Securities Maintains Neutral on Kymera Therapeutics, Lowers Price Target to $44

Barclays analyst Ryan Macwilliams maintains EverCommerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVCM#NASDAQ">EVCM</a>) with a Equal-Weight and raises the price target from $9 to $11.

EVCM

Barclays Maintains Equal-Weight on EverCommerce, Raises Price Target to $11

Guggenheim analyst Michael Schmidt reiterates SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) with a Neutral and maintains $47 price target.

SWTX

Guggenheim Reiterates Neutral on SpringWorks Therapeutics, Maintains $47 Price Target

Gold and silver are trading lower after the US and China agreed to a temporary reduction in most tariffs on each other's goods. This could be driving a rotation out of safe-haven assets.

Barclays analyst Ramsey El-Assal maintains EPAM Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) with a Overweight and raises the price target from $200 to $215.

EPAM

Barclays Maintains Overweight on EPAM Systems, Raises Price Target to $215

<a href="https://www.philips.com/a-w/about/news/archive/standard/news/articles/2025/philips-collaborates-with-nvidia-to-improve-patient-care-in-mr-with-latest-ai-advances#:~:text=Philips%20collaborates%20with%20NVIDIA%20to,MR%20with%20latest%20AI%20advances&amp;text=From%20cutting%20scan%20times%2C%20to,for%20their%20patients%20%5B1%5D.">https://www.philips.com/a-w/about/news/archive/standard/news/articles/2025/philips-collaborates-with-nvidia-to-improve-patient-care-in-mr-with-latest-ai-advances#:~:text=Philips%20collaborates%20with%20NVIDIA%20to,MR%20with%20latest%20AI%20advances&amp;text=From%20cutting%20scan%20times%2C%20to,for%20their%20patients%20%5B1%5D.</a>
&nbsp;
From cutting scan times, to speeding workflow and improving image quality, Philips is already empowering healthcare providers with AI-powered solutions to deliver faster, more accurate diagnoses for their patients [1]. Today at a major industry gathering <a href="https://www.usa.philips.com/healthcare/event/upcoming/ismrm-2025">ISMRM</a>, the company announced a new breakthrough collaboration with NVIDIA to harness cutting-edge advances in AI for MR imaging.
 &nbsp;

NVDA

Reported Earlier: 'Philips Collaborates With NVIDIA To Improve Patient Care In MR With Latest AI Advances' - Phillips

Guggenheim analyst John Heinbockel reiterates Xponential Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) with a Buy and maintains $13 price target.

XPOF

Guggenheim Reiterates Buy on Xponential Fitness, Maintains $13 Price Target

SHOP

Shopify shares are trading higher after it was announced the stock will join the Nasdaq-100 beginning May 19.

Hamilton Beach Brands Holdings shares are trading higher after the company raised its quarterly cash dividend.

Legal

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fortrea Holdings Inc. - FTRE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE

Fortrea Announces Date for First Quarter 2025 Financial Results and Conference Call

Fortrea Named a Leader in Everest Group's Pharmacovigilance Operations PEAK Matrix® Assessment 2025

Management

Fortrea Announces CEO Stepping Down

Earnings

Fortrea Reports First Quarter 2025 Results

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Atlantic International Corp. - Common Stock

Atlantic International

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Codexis

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Standard BioTools

Lifecore Biomedical

Mesa Laboratories

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences

MaxCyte

Niagen Bioscience

Pacific Biosciences of California, Inc. - Common Stock

Pacific Biosciences

Personalis

Quantum-Si Incorporated - Class A Common Stock

Quantum-Si

Quanterix

Sotera Health

Stevanato Group

Alpha Teknova

10x Genomics

Barclays

Mizuho

Evercore ISI Group

Goldman Sachs

Citigroup

월요일 아침 (현지 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데, 오늘 투자자들의 관심을 끌 수 있는 일부 주식은 다음과 같다:
<ul>
<li>월스트리트는 먼데이닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>)이 개장 전 2억 2,877만 달러의 매출과 주당 56센트의 분기 이익을 보고할 것으로 예상하고 있다. 먼데이닷컴의 주가는 시간외 거래에서 1% 상승한 228.00달러를 기록했다.</li>
<li>분석가들은 선 라이프 파이낸셜(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLF#NYSE">SLF</a>)이 분기 이익을 주당 1.14달러, 매출 8억 8,725만 달러로 기록할 것으로 예상하고 있다. 이 회사는 시장이 마감된 후 실적을 발표할 예정이다. 선 라이프의 주식은 시간외 거래에서 0.02% 상승한 48.10달러를 기록했다.</li>
<li>BRT 아파트먼트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRT#NYSE">BRT</a>)의 2분기 이익은 주당 35센트로 시장 예상치인 주당 28센트를 넘어섰다. 이 회사는 분기별 매출이 2,386만 달러로 분석가의 합의 추정치인 2,360만 달러를 넘어섰다. BRT 아파트먼트의 주가는 금요일에 1.9% 하락한 17.55달러로 마감했다.</li>
</ul>
여기에서 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener" data-google-interstitial="false">프리마켓 시황</a>을 확인하세요.
<ul>
<li>개장하기 전에 포트레아 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>)는 6억 8,908만 달러의 매출과 주당 8센트의 분기 이익을 보고할 것으로 예상된다. 포트레아의 주가는 시간외 거래에서 0.2% 하락한 25.12달러를 기록했다.</li>
<li>애널리스트들은 KE 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NASDAQ">BEKE</a>)가 개장 전 매출 30억 6천만 달러에 주당 21센트의 분기 이익을 공시할 것으로 예상하고 있다. KE 홀딩스의 주가는 시간외 거래에서 0.4% 상승한 14.09달러를 기록했다.</li>
</ul>
사진제공: 셔터스톡
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요

Comments

Fortrea Holdings

뉴스

에 대한 최신 뉴스 Fortrea Holdings (NASDAQ:FTRE) 주식

월요일, 8월 12, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌